STOK — Stoke Therapeutics, Inc.

Summary of STOK Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of the end of Q2 2026, STOK reported $354.3 million in cash, cash equivalents, and marketable securities. Following a recent capital raise, the pro forma cash position is approximately $420 million, which is expected to fund operations through a potential U.S. launch of zorevunersen by early 2028.

2. Strategic Updates and Business Highlights

• Phase III EMPEROR Study: Enrollment of 162 patients has been completed, with no treatment discontinuations reported. The study is on track for a data readout in Q3 2027, which will support the NDA submission.
• Regulatory Plans: A pre-NDA meeting with the FDA is scheduled for later this year. The rolling NDA submission is expected to begin in Q1 2027, starting with the chemistry, manufacturing, and controls (CMC) module.
• Pipeline Development: Progress is being made on STK-002 for autosomal dominant optic atrophy (ADOA), with a Phase I study underway. Additionally, early research efforts are expanding into haploinsufficient diseases.
• Commercial Strategy: The company is preparing for a U.S. launch of zorevunersen, targeting a patient population of approximately 16,000 in the U.S., with a focus on centers of excellence.

3. Forward Guidance and Outlook

• NDA Submission Timeline: The company anticipates initiating its NDA submission in Q1 2027 and completing it by Q3 2027 with clinical data.
• Market Potential: The introduction of zorevunersen is expected to significantly increase genetic testing rates among the Dravet syndrome population, with estimates suggesting an 85-90% increase in diagnosis rates post-launch.
• Long-term Data: STOK plans to leverage six years of safety and efficacy data from open-label extension studies to support its NDA and commercial positioning.

4. Bad News, Challenges, or Points of Concern

• Regulatory Risks: The success of the NDA submission and subsequent approval is contingent on the outcomes of the EMPEROR study, which carries inherent risks associated with clinical trials.
• Market Competition: The company faces competition from existing treatments for Dravet syndrome, and the market dynamics could shift with the introduction of new therapies.
• Execution Risks: The need for effective execution in commercial readiness and regulatory compliance is critical as the company approaches potential product launch.

5. Notable Q&A Insights

• Study Metrics: Analysts inquired about the metrics from the EMPEROR study, with management expressing confidence in the study's design and the absence of patient dropouts.
• NDA Submission Details: There was discussion about the specifics of the NDA submission, including the statistical analysis plan and the hierarchy of secondary endpoints, particularly concerning the Vineland-3 assessments.
• Market Research Feedback: Feedback from healthcare providers and payers indicates that long-term data from open-label studies will be crucial for acceptance and reimbursement of zorevunersen.
• Commercial Infrastructure: The company is confident in its ability to leverage existing relationships with healthcare providers and the experience of treatment centers to facilitate a smooth launch.

Overall, STOK is making significant progress in its clinical programs and is well-positioned financially for upcoming regulatory submissions and potential product launches, although it must navigate the complexities of clinical trial outcomes and market competition.